相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus The AleCardio Randomized Clinical Trial
A. Michael Lincoff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer
J. R. Colca et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models
Ying Chen et al.
DIABETES (2013)
Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
Bertrand Cariou et al.
DIABETES CARE (2013)
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Sunder Mudaliar et al.
GASTROENTEROLOGY (2013)
Hepatoprotective Effects of the Dual Peroxisome Proliferator-Activated Receptor Alpha/Delta Agonist, GFT505, in Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Bart Staels et al.
HEPATOLOGY (2013)
Harnessing the benefits of PPARIβ/δ agonists
Louise S. Mackenzie et al.
LIFE SCIENCES (2013)
A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use
Sihao Liu et al.
NATURE (2013)
The role of hepatokines in metabolism
Norbert Stefan et al.
NATURE REVIEWS ENDOCRINOLOGY (2013)
Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis
E. Boettcher et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Roles of PPARs in NAFLD: Potential therapeutic targets
Anne Tailleux et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2012)
Cellular and molecular mechanisms of metformin: an overview
Benoit Viollet et al.
CLINICAL SCIENCE (2012)
Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment The FIELD Study
Ru-Dee Ting et al.
DIABETES CARE (2012)
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
S. E. Inzucchi et al.
DIABETOLOGIA (2012)
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani et al.
HEPATOLOGY (2012)
Medication Adherence in Type 2 Diabetes: The ENTRED Study 2007, a French Population-Based Study
Michel Tiv et al.
PLOS ONE (2012)
Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
Keiko Iwaisako et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Thiazolidinediones and PPARγ agonists: time for a reassessment
Bertrand Cariou et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2012)
Peroxisome Proliferator-Activated Receptor-α Gene Level Differently Affects Lipid Metabolism and Inflammation in Apolipoprotein E2 Knock-In Mice
Fanny Lalloyer et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
Bertrand Cariou et al.
DIABETES CARE (2011)
CHRONIC KIDNEY DISEASE Do fibrates truly preserve kidney function?
Suneel M. Udani et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment
Briohny W. Smith et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact
Esther Phielix et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2011)
Fibrates, Glitazones, and Peroxisome Proliferator-Activated Receptors
Fanny Lalloyer et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome
Renata Belfort et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
A position statement on NAFLD/NASH based on the EASL 2009 special conference
Vlad Ratziu et al.
JOURNAL OF HEPATOLOGY (2010)
Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes.
Emily Y. Chew et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Roles of liver innate immune cells in nonalcoholic fatty liver disease
Yu-Tao Zhan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses
Leena Juurinen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice
Catherine Postic et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Fibrates and future PPAR alpha agonists in the treatment of cardiovascular disease
Bart Staels et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2008)
Activation of peroxisome proliferator-activated receptor (PPAR)δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatly acid oxidation in moderately obese men
Ulf Riserus et al.
DIABETES (2008)
Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus
M. Bajaj et al.
DIABETOLOGIA (2007)
Peroxisome proliferator-activated receptor α protects against obesity-induced hepatic inflammation
Rinke Stienstra et al.
ENDOCRINOLOGY (2007)
Triglyceride:: High-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist
Dennis L. Sprecher et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome
Catherine Fievet et al.
CURRENT OPINION IN PHARMACOLOGY (2006)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Sorting out the roles of PPARα in energy metabolism and vascular horneostasis
P Lefebvre et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
PPARδ regulates glucose metabolism and insulin sensitivity
CH Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The metabolic syndrome as a predictor of nonalcoholic fatty liver disease
M Hamaguchi et al.
ANNALS OF INTERNAL MEDICINE (2005)
Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome
T Tanaka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Insulin signalling and the regulation of glucose and lipid metabolism
AR Saltiel et al.
NATURE (2001)
Cellular mechanisms of insulin resistance
GI Shulman
JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
